Intrinsic Imaging Awarded New Clinical Study to Evaluate Innovative Tumor Imaging Platform

Phase II clinical trial evaluating a novel imaging platform that distinguishes malignant from non-malignant tissue.

Bolton, MA / San Antonio, TX

Bolton, MA / San Antonio, TX — July 6, 2017 — Intrinsic Imaging, a full-service medical imaging core lab providing comprehensive services in support of clinical trials and medical device trials, announces today the award of a Phase II Clinical Trial to evaluate the ability of a novel imaging platform that assists physicians in distinguishing various malignant tissue types from non-malignant tissue.

Intrinsic Imaging has extensive experience in imaging for medical device development. This trial allows the company to utilize this strength to support development of novel imaging platforms in oncology. Intrinsic Imaging is leading the integration of novel methodologies in evaluating new medical imaging technologies for numerous oncology specific medical devices as well as drug product trials where applicable.

Throughout this trial, Intrinsic Imaging will provide comprehensive imaging core lab services including, but not limited to, study management, protocol and charter development, site qualification, site training and management, image transfer, quality control and processing. With its portfolio of five ISO certifications, Intrinsic Imaging has the most comprehensive and sophisticated quality management system in the industry.

"Intrinsic Imaging is an industry leader in conducting medical device imaging trials," said Todd Joron, President and COO at Intrinsic Imaging. "We are extremely pleased to be a critical partner in this medical device trial and help bring this innovative product closer to market."

About Intrinsic Imaging, LLC

Intrinsic Imaging is an ISO certified medical imaging CRO and imaging core lab providing comprehensive services in support of Phase I-IV clinical trials and Class I, II, III medical device trials. Intrinsic Imaging is also a world leader in conducting Artificial Intelligence studies. With its team of more than 650 board-certified and fellowship-trained physicians, Intrinsic Imaging's team has sub-specialization in all therapeutic areas, including Cardiovascular, Central Nervous System,Gastroenterology, Musculoskeletal, Oncology and Ophthalmology. Certified by the British Standards Institution (BSI), Intrinsic Imaging is the only company in the world to hold five ISO certifications specifically for providing imaging core lab services on clinical trials. For more information, please visit www.IntrinsicImaging.com.

Contact:

Intrinsic Imaging, LLC
580 Main St., Suite 210
Bolton, MA, 01740, USA
+1 978-616-4650
Contact@IntrinsicImaging.com